Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Worm-Fighting combo pill tested in kids, but trial stopped early

NCT ID NCT05124691

Disease control Sponsor: Barcelona Institute for Global Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a new pill combining two drugs (albendazole and ivermectin) to treat several types of intestinal worms in children and young adults aged 5 to 18. The goal was to see if the combination worked better than the standard single drug. However, the trial was terminated early, so the planned results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
albendazole and ivermectin combination pill
What this could lead to
If it had succeeded, this combination could have offered a more effective single treatment for several types of intestinal worms, especially those resistant to current drugs.
What could go wrong
The trial was terminated, so we don't have full results. Early-stage research often fails to show benefit or may reveal safety issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

1,001 people

The number who actually took part.

Started

Jan 2022

Finished

Mar 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

5 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Positive infection test by microscopy for at least one of the following STH: T. trichiura, hookworms and/or larvae of S. stercoralis. * Weight ≥15 Kg. * Male or female, aged 5 to 18 years. * Female participants who are ≥12 years old (or female post menarche) must have a negative urine pregnancy test at screening or at the time of randomization. * Ability to take oral medication and willingness to comply with all study procedures. * Parental acceptance to participate in the study by obtaining a signed and dated informed consent form approved by the Regulatory authorities. In addition, verbal assent will be obtained from children aged 12-18 years. Exclusion Criteria: * Intake of ALB, mebendazole and/or IVM, or any potentially interacting drug three months before screening. * Residence outside the study area or planning to move away in the four weeks following recruitment. * Epidemiological risk of infection by Loa loa. * Serious medical illness, per investigator's criteria. * Any participant's condition that would prevent the appropriate evaluation and followup, as per investigator's criteria. * Known hypersensitivity to any components of either of the study treatment. * Positive pregnancy urine test, pregnant or first week postpartum.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Helminthes; infestation, intestinal are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

helminthiasis hookworm infectious disease intestinal helminthiasis strongyloidiasis trichuriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Helminthes; infestation, intestinal

Contacts and locations

Locations

  • Bahir Dar University, Colleges of Medicine and Health Sciences (BDU-CMHS)

    Bahir Dar, P.O. Box 79, Ethiopia

  • Centro de Investigação em Saúde da Manhiça (CISM)

    Manhiça, Maputo Province, 1929, Mozambique

  • Kenya Medical Research Institute (KEMRI)

    Nairobi, 54840-00200, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.